Zevra Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	84.39	23.61	27.46	10.16	28.65	13.29
Revenue Growth (YoY)	244.60%	-14.02%	170.26%	-64.53%	115.61%	3.50%
Cost of Revenue	16.33	7.42	2.17	0.22	2.06	1.31
Gross Profit	68.06	16.2	25.29	9.94	26.59	11.98
Selling, General & Admin	73.44	54.92	35.09	15.61	9.23	8.44
Research & Development	18.42	42.04	39.03	19.23	9.64	8.32
Amortization of Goodwill & Intangibles	5.16	6.24	0.77	-	-	-
Operating Expenses	97.02	103.2	74.89	34.84	18.86	16.76
Operating Income	-28.96	-87	-49.6	-24.9	7.73	-4.78
Interest Expense	-8.22	-7.35	-1.5	-0.34	-0.38	-7.09
Interest & Investment Income	5.16	2.18	4.54	1.51	0.26	0.09
Other Non Operating Income (Expenses)	-3.98	2.06	-0.1	15.16	-0.03	-0.18
EBT Excluding Unusual Items	-36.01	-90.12	-46.66	-8.57	7.59	-11.97
Merger & Restructuring Charges	-	-	-	-	-	-0.83
Gain (Loss) on Sale of Investments	0.04	-0.02	0.61	-0.58	-0.01	-
Other Unusual Items	-	-	-	-	-16.1	-
Pretax Income	53.64	-90.14	-46.05	-26.81	-8.52	-12.79
Income Tax Expense	18.32	15.37	-	-0.03	0.03	-0.03
Net Income	35.33	-105.51	-46.05	-26.77	-8.56	-12.76
Preferred Dividends & Other Adjustments	5.31	-	-	-	54.34	-
Net Income to Common	30.02	-105.51	-46.05	-26.77	-62.9	-12.76
Shares Outstanding (Basic)	55	46	35	34	30	4
Shares Outstanding (Diluted)	56	46	35	34	30	4
Shares Change (YoY)	31.47%	30.46%	2.79%	15.87%	647.72%	114.79%
EPS (Basic)	0.55	-2.28	-1.30	-0.78	-2.11	-3.21
EPS (Diluted)	0.54	-2.28	-1.30	-0.78	-2.11	-3.21
Free Cash Flow	-24.23	-69.67	-33.83	-18.81	10.34	-1.97
Free Cash Flow Per Share	-0.43	-1.51	-0.95	-0.55	0.35	-0.49
Gross Margin	80.65%	68.59%	92.09%	97.81%	92.81%	90.18%
Operating Margin	-34.32%	-368.47%	-180.63%	-245.07%	26.98%	-35.98%
Profit Margin	35.57%	-446.85%	-167.69%	-263.48%	-219.54%	-96.03%
Free Cash Flow Margin	-28.71%	-295.04%	-123.20%	-185.12%	36.08%	-14.84%
EBITDA	-23.62	-80.61	-48.6	-23.96	7.99	-4.51
EBITDA Margin	-27.99%	-	-176.97%	-235.78%	27.87%	-33.92%
D&A For EBITDA	5.34	6.39	1.01	0.94	0.26	0.27
EBIT	-28.96	-87	-49.6	-24.9	7.73	-4.78
EBIT Margin	-34.32%	-	-180.63%	-245.07%	26.98%	-35.98%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q